|Researchers at Purdue University have developed new quinolone-based inhibitors for autoimmune diseases and cancers caused by mutations to the PTPN22 gene. PTPN22 encodes an enzyme, lymphoid-specific tyrosine phosphatase (Lyp) that is associated with the immune system through its regulation of the T-cell receptor signaling pathway. Mutations to PTPN22 are present in individuals with diseases including type-1 diabetes, Graves' disease, Addison's disease, vitiligo, juvenile arthritis, systemic lupus, and Hashimoto thyroiditis. To date there are no Lyp inhibitors approved as drugs, and current Lyp inhibitors exhibit poor selectivity for Lyp among other phosphatases. Purdue researchers have created a Lyp inhibitor that can be synthesized with 65-90% yield and over 95% purity as verified by hydrogen and carbon nuclear magnetic resonance spectroscopy. The new compound inhibits Lyp with a 1.4 micromolar half maximal inhibitory concentration and exhibits promising pharmacokinetic properties in mice. In addition, Purdue researchers observed a 7- to 10-fold improvement in Lyp selectivity over other current drug candidates.
-Promotes Immune Response to Eliminate Tumors
-High Cell Permeability
-Excellent Yield and Purity
-PTPN22 Triggered Autoimmune Disease Treatment and Cancer Immunotherapy
The new inhibitors developed by Purdue researchers have been tested in an enzyme inhibition assay and for pharmacokinetic properties in mice.
Systemic inhibition of PTPN22 augments anticancer immunity
J Clin Invest. 2021. https://doi.org/10.1172/JCI146950.
Feb 5, 2021
Feb 5, 2021
Apr 14, 2020
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486